2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchMeSH KeywordsBinge-Eating DisorderBulimiaBupropionDouble-Blind MethodFemaleHumansMaleMiddle AgedNaltrexoneObesityTreatment OutcomeWeight LossConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2019
Commentary on Tosun et al. (2019): Dynamic changes in sex hormones and smoking cessation
Peltier MR, McKee SA. Commentary on Tosun et al. (2019): Dynamic changes in sex hormones and smoking cessation. Addiction 2019, 114: 1814-1815. PMID: 31347245, PMCID: PMC6732031, DOI: 10.1111/add.14728.Peer-Reviewed Original ResearchAlcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder
Verplaetse TL, Ralevski E, Roberts W, Gueorguieva R, McKee SA, Petrakis IL. Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder. Alcohol Clinical And Experimental Research 2019, 43: 741-746. PMID: 30698839, PMCID: PMC6443463, DOI: 10.1111/acer.13969.Peer-Reviewed Original ResearchConceptsAlcohol use disorderPosttraumatic stress disorderPlacebo-treated individualsTotal CAPS scoresClinical trialsCAPS scoresPrazosin treatmentComorbid populationPTSD symptomsUse disordersClinician-Administered PTSD Scale scoresDouble-blind clinical trialStress disorderComorbid alcohol use disorderPrazosin-treated groupSymptoms of PTSDRecent clinical trialsComorbid alcohol dependenceCourse of treatmentΑ1-adrenergic antagonistPosttraumatic stress disorder (PTSD) symptomsOngoing symptomsSleep disturbancesMedication effectsNoradrenergic system
2018
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol DrinkingAlcoholismDouble-Blind MethodFemaleHumansMaleMecamylamineMiddle AgedNicotinic AntagonistsTobacco SmokingTreatment OutcomeConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differencesA preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers
Roberts W, Verplaetse TL, Moore KE, Oberleitner LM, McKee SA. A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers. Human Psychopharmacology Clinical And Experimental 2018, 33: e2660. PMID: 29878501, PMCID: PMC5995328, DOI: 10.1002/hup.2660.Peer-Reviewed Original ResearchConceptsContinuous performance taskInhibitory controlCognitive functioningPerformance taskTobacco withdrawalEffects of doxazosinSustained attentionCognitive performanceWithdrawal symptomsCognitive AssessmentSmoking outcomesMost measuresSelf-reported withdrawal symptomsReaction timeTaskParticipantsFunctioningPredrug levelsΑ1 antagonistTitration periodGreater improvementDoxazosinSmokingSymptomsPreliminary investigationEffects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users
Roberts W, Shi JM, Tetrault JM, McKee SA. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users. Journal Of Addiction Medicine 2018, 12: 227-233. PMID: 29438157, PMCID: PMC5970035, DOI: 10.1097/adm.0000000000000392.Peer-Reviewed Original ResearchConceptsLow-dose naltrexoneTobacco usersTreatment outcomesPlacebo-controlled human laboratory studySmoking cessation treatmentEffects of vareniclineCigarettes ad libitumHuman laboratory studiesSubjective drug effectsVarenicline monotherapyCessation medicationsMedication therapyCessation treatmentMedication armTobacco useVareniclineLow doseSmoking relapseSmokingDrug effectsSmoking outcomesSmoking behaviorNaltrexoneCarbon monoxide levelsHeavy drinkersPilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior
Verplaetse TL, Weinberger AH, Ashare RL, Pittman BP, Shi JM, Tetrault JM, Lavery M, McKee SA. Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior. Journal Of Psychopharmacology 2018, 32: 1003-1009. PMID: 29692206, PMCID: PMC6258014, DOI: 10.1177/0269881118767647.Peer-Reviewed Original ResearchConceptsEffects of carvedilolSmoking lapse behaviorAdrenergic antagonistsTobacco cravingSmoking outcomesPhysiologic reactivitySystolic blood pressureNumber of cigarettesNicotine-motivated behaviors× time effectSelf-administration periodEffects of α1Human laboratory modelNicotine-deprived smokersPlacebo groupBlood pressureAdrenergic antagonismMedication conditionClinical indicationsNoradrenergic systemSubsequent smokingHeart rateProperties of drugsSmokingCarvedilolEffects of Varenicline on Cognitive Performance in Heavy Drinkers: Dose-Response Effects and Associations With Drinking Outcomes
Roberts W, McKee SA. Effects of Varenicline on Cognitive Performance in Heavy Drinkers: Dose-Response Effects and Associations With Drinking Outcomes. Experimental And Clinical Psychopharmacology 2018, 26: 49-57. PMID: 29389170, PMCID: PMC5797996, DOI: 10.1037/pha0000161.Peer-Reviewed Original ResearchConceptsAlcohol use disorderCognitive functioningCognitive assessment batteryContinuous performance taskAdult heavy drinkersSignificant indirect effectUse disordersReaction timeEffects of vareniclinePerformance taskHeavy drinkersCognitive outcomesAssessment BatteryHuman laboratory experimentsCognitive functionMediation analysisDrinking outcomesMemoryLess drinkingAlcohol useDrinking behaviorIndirect effectsLaboratory sessionsDrinking taskVarenicline dose
2017
Effects of varenicline on alcohol cue reactivity in heavy drinkers
Roberts W, Harrison ELR, McKee SA. Effects of varenicline on alcohol cue reactivity in heavy drinkers. Psychopharmacology 2017, 234: 2737-2745. PMID: 28600734, PMCID: PMC5709183, DOI: 10.1007/s00213-017-4667-9.Peer-Reviewed Original ResearchConceptsEffects of vareniclineHuman laboratory studiesAlcohol use disorderAlcohol cue reactivityHeavy drinkersUse disordersPlacebo-controlled human laboratory studyCue exposureAlcohol useCue reactivityUse of vareniclineFront-line treatmentCue-induced alcohol cravingAlcohol cue exposureTitration periodCue-reactivity paradigmMedication groupPharmacological treatmentMedication effectsAdult smokersTobacco cravingVareniclineMethodsAs partLarge seriesAlcohol craving
2016
Effect of Varenicline Combined with High‐Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings
Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Varenicline Combined with High‐Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings. Alcohol Clinical And Experimental Research 2016, 40: 1567-1576. PMID: 27246567, PMCID: PMC4930423, DOI: 10.1111/acer.13110.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol-Related DisordersAlcoholic IntoxicationAssociation LearningBlood PressureCravingDose-Response Relationship, DrugDouble-Blind MethodEthanolExecutive FunctionFemaleHeart RateHumansMaleMemory, Short-TermNicotinic AgonistsPsychological TestsPsychomotor PerformanceVareniclineYoung AdultConceptsPerceptual-motor functionAlcohol use disorderExecutive cognitive functionCognitive functionDose of alcoholSubjective reactivitySubjective intoxicationHigh-dose alcoholNonalcoholic control beverageAlcohol-motivated behaviorsUse disordersEffects of vareniclineAssociative learningAversive eventsLaboratory paradigmDiastolic blood pressureAlcohol cravingControl beverageMotor responsePhysiologic reactivityAlcohol-related increasesLaboratory sessionsMotor functionBlood pressurePreliminary investigationEffect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders
Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders. Journal Of Addiction Medicine 2016, 10: 166-173. PMID: 27159341, PMCID: PMC4880525, DOI: 10.1097/adm.0000000000000208.Peer-Reviewed Original ResearchConceptsAlcohol use disorderEffects of vareniclineAlcohol consumptionUse disordersVarenicline doseD dosePlasma levelsDose of vareniclineDoses of vareniclineFrequency of insomniaPlacebo-controlled investigationHigher plasma levelsDose of alcoholAlcohol Self-AdministrationSelf-administration periodMedication pretreatmentAdverse eventsEdition criteriaVareniclineLow doseSide effectsAlcohol cravingMeeting criteriaPhysiologic responsesAlcohol-related outcomes
2015
Transcranial Direct Current Brain Stimulation Increases Ability to Resist Smoking
Falcone M, Bernardo L, Ashare RL, Hamilton R, Faseyitan O, McKee SA, Loughead J, Lerman C. Transcranial Direct Current Brain Stimulation Increases Ability to Resist Smoking. Brain Stimulation 2015, 9: 191-196. PMID: 26572280, PMCID: PMC4789149, DOI: 10.1016/j.brs.2015.10.004.Peer-Reviewed Original ResearchConceptsTranscranial direct current stimulationDorsolateral prefrontal cortexLeft dorsolateral prefrontal cortexActive transcranial direct current stimulationMA anodal stimulationAnodal stimulationSmoking cessation treatmentSmoking behavior changeSelf-reported smokingDirect current stimulationSecondary outcomesCessation treatmentWashout periodFirst cigaretteCigarette cravingOvernight abstinenceTDCS sessionsSmoking sessionCigarette consumptionSmokingTherapeutic potentialCurrent stimulationPrefrontal cortexCognitive control circuitsCathodal stimulation
2014
A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation
McKee SA, Potenza MN, Kober H, Sofuoglu M, Arnsten A, Picciotto MR, Weinberger AH, Ashare R, Sinha R. A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation. Journal Of Psychopharmacology 2014, 29: 300-311. PMID: 25516371, PMCID: PMC4376109, DOI: 10.1177/0269881114562091.Peer-Reviewed Original ResearchConceptsPlacebo-treated subjectsFunctional magnetic resonance imagingCentral noradrenergic pathwaysPrefrontal cognitive dysfunctionSystolic blood pressureClinical outcome dataAd libitum smokingNovel translational approachStress-induced reinstatementMagnetic resonance imagingNicotine-deprived smokersBlood pressureNoradrenergic pathwaysAgonist guanfacineCognitive dysfunctionTreatment periodTobacco cravingQuit attemptsOutcome dataSmokingComplete abstinenceCortisol levelsTranslational investigationsCigarette useGuanfacine
2013
A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self‐administration
Udo T, Harrison EL, Shi J, Tetrault J, McKee SA. A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self‐administration. American Journal On Addictions 2013, 22: 590-597. PMID: 24131167, PMCID: PMC3934424, DOI: 10.1111/j.1521-0391.2013.12014.x.Peer-Reviewed Original ResearchConceptsSelf-administration periodNicotine nasal sprayHeavy drinking smokersNasal sprayNicotine patchAlcohol responsesPriming drinkSerum nicotine levelsPlacebo-controlled studyNicotine replacement therapySubjective alcohol responsesPositive subjective responsesNumber of drinksPlacebo administrationReplacement therapyPriming doseSmoking relapseAlcohol consumptionPlacebo conditionPatch applicationNicotine levelsClinical settingPilot studySmokersSubjective responses
2012
Effects of Varenicline and Bupropion on Cognitive Processes Among Nicotine-Deprived Smokers
Ashare RL, McKee SA. Effects of Varenicline and Bupropion on Cognitive Processes Among Nicotine-Deprived Smokers. Experimental And Clinical Psychopharmacology 2012, 20: 63-70. PMID: 21942262, PMCID: PMC3640636, DOI: 10.1037/a0025594.Peer-Reviewed Original ResearchConceptsNicotine deprivationCognitive processesMeasures of attentionNicotine-deprived smokersMeasures of cravingEffects of vareniclineNegative affectOvernight abstinenceCurrent data highlightMemoryReduced accuracyDaily smokersCurrent sampleDifficulty concentratingLaboratory sessionsEffects of bupropionFuture researchReaction timeSex differencesRecent researchAbstinence ratesDeficitsNew pharmacological treatmentsParticipantsSmoking cessationSex differences in stimulus expectancy and pharmacologic effects of a moderate dose of alcohol on smoking lapse risk in a laboratory analogue study
Kahler CW, Metrik J, Spillane NS, Leventhal AM, McKee SA, Tidey JW, McGeary JE, Knopik VS, Rohsenow DJ. Sex differences in stimulus expectancy and pharmacologic effects of a moderate dose of alcohol on smoking lapse risk in a laboratory analogue study. Psychopharmacology 2012, 222: 71-80. PMID: 22227611, PMCID: PMC3687530, DOI: 10.1007/s00213-011-2624-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol DrinkingCentral Nervous System DepressantsDouble-Blind MethodEthanolFemaleHumansMaleMiddle AgedPersonal SatisfactionSex FactorsSmokingConceptsInstruction conditionPharmacologic effectsStimulus expectancyQuit smoking attemptsDirect pharmacologic effectInitial lapseHeavy alcohol drinkersLapse riskLaboratory analog studiesPlacebo designBeverage contentSmoking attemptsAnalogue studyAlcohol drinkersGreater satisfactionModerate doseSex differencesSmoking behaviorPharmacological effectsSmokingNonalcoholic beveragesTaskCondition effectsSatisfactionInstruction
2011
Preliminary Findings on the Interactive Effects of IV Ethanol and IV Nicotine on Human Behavior and Cognition: A Laboratory Study
Ralevski E, Perry EB, D’Souza D, Bufis V, Elander J, Limoncelli D, Vendetti M, Dean E, Cooper TB, McKee S, Petrakis I. Preliminary Findings on the Interactive Effects of IV Ethanol and IV Nicotine on Human Behavior and Cognition: A Laboratory Study. Nicotine & Tobacco Research 2011, 14: 596-606. PMID: 22180582, PMCID: PMC6281082, DOI: 10.1093/ntr/ntr258.Peer-Reviewed Original ResearchConceptsRey Auditory Verbal Learning TaskAuditory Verbal Learning TaskVerbal learning taskAcute intravenous alcoholSubjective alcohol effectsBiphasic Alcohol Effects ScaleAlcohol-induced deficitsAlcohol-induced impairmentDoses of alcoholActive nicotineInteractive effectsTest dayCognitive inhibitionVerbal learningCognitive performanceLearning taskSubjective intoxicationAlcohol effectsHuman behaviorNicotine effectsIntravenous alcoholAlcohol infusionManner oneSubjective effectsCognitionEffects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers
Herman AI, Waters AJ, McKee SA, Sofuoglu M. Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers. Psychopharmacology 2011, 220: 611-617. PMID: 21947318, PMCID: PMC3654651, DOI: 10.1007/s00213-011-2507-x.Peer-Reviewed Original ResearchConceptsPregabalin treatmentSmoking behaviorWithdrawal symptomsTreatment periodAd lib smoking behaviorCognitive performanceEffect of pregabalinTobacco withdrawal symptomsDays of treatmentPregabalin effectCrossover studyWashout periodNicotine withdrawalGABA neurotransmissionNicotine rewardSmoking periodTobacco withdrawalAbstinent smokersBrain glutamateClinical studiesNicotine addictionSmokersPregabalinConclusionsThese findingsGABA analogues
2010
Differences in smoking expectancies in smokers with and without a history of major depression
Weinberger AH, George TP, McKee SA. Differences in smoking expectancies in smokers with and without a history of major depression. Addictive Behaviors 2010, 36: 434-437. PMID: 21239119, PMCID: PMC3052745, DOI: 10.1016/j.addbeh.2010.12.024.Peer-Reviewed Original ResearchConceptsHistory of depressionMajor depressive disorderSmoking cessationClinical trialsSmoking expectanciesAdult cigarette smokersInteraction of depressionSmoking cessation behaviorsLower quit ratesMDD- smokersCigarette smokersDepressive disorderAdult smokersCognitive-behavioral treatmentMajor depressionQuit ratesCessation behaviorsSmokersSelegiline hydrochlorideSmokingSecondary aimEvidence high ratesDepressionSmoking beliefsHigh rate
2009
Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: A preliminary study
McKee SA, Weinberger AH, Harrison EL, Coppola S, George TP. Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: A preliminary study. Schizophrenia Research 2009, 115: 317-324. PMID: 19700263, PMCID: PMC2784178, DOI: 10.1016/j.schres.2009.07.019.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBehavior, AddictiveDouble-Blind MethodFemaleHumansMaleMecamylamineMiddle AgedNeuropsychological TestsNicotinic AntagonistsReaction TimeSchizophreniaSelf AdministrationSmokingSmoking CessationSubstance Withdrawal SyndromeSurveys and QuestionnairesTobacco Use DisorderYoung AdultConceptsAd lib smoking behaviorNicotine levelsSmoking behaviorControl smokersSmoking topographyNicotinic receptor antagonist mecamylamineNicotinic acetylcholine receptor antagonistHealthy control smokersHigh-affinity nAChRsIntensity of smokingAd lib smokingEffects of mecamylamineNumber of cigarettesPlacebo-controlled designAcetylcholine receptor antagonistNicotine exposureAntagonist mecamylamineCompensatory smokingReceptor antagonistSmoking intensityMecamylamineSmokersSmokingSchizophreniaPreliminary study